How the once-dominant cancer company has overhauled its strategy for long-term growth

70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas

Advice for CEOs and CFOs as they navigate the year ahead

Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development

Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products

Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing

Plus: Results from Relay, Centessa, Viridian, Amgen and more

Will bispecifics be the drugs to dethrone cancer’s biggest blockbusters? Akeso aims to find out with ivonescimab

BioCentury’s weekly deals analysis

Pharma outlines goals for oncology business as it moves to integrate ADC play Seagen